Report of specific cardiovascular outcomes of the ADVANTAGE trial.
Braunstein
Ned
N
Polis
Adam
A
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000150:complications*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009288:Naproxen / Q000009:adverse effects*; D010003:Osteoarthritis / Q000188:drug therapy; D013450:Sulfones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen